A Pilot Study of OncoSil™ Given to Patients With Pancreatic Cancer Treated With Gemcitabine +/- Nab-paclitaxel.

Completed · Not applicable

Conditions studied: Unresectable Locally Advanced Pancreatic Carcinoma

In brief

To evaluate the safety of OncoSil™ in a patient population undergoing standard chemotherapy treatment for pancreatic cancer. This study has been designed to satisfy FDA regulatory requirements. The clinical investigation will be conducted at approximately 5 sites in the United States involving 20 patients.

Key facts

Study ID

NCT03076216

Run by

OncoSil Medical Limited

People needed

9

Starts

2017-08-01

Expected to finish

2020-11-28

Last updated by the study team

2021-07-13

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Histologically or cytologically proven adenocarcinoma of the pancreas.
• Stage III unresectable locally advanced pancreatic carcinoma. Patients with technically resectable tumors (T1-T3) will also be eligible, if they are deemed unresectable due to medical comorbidities or refusal of surgery.
• Pancreatic target tumor diameter of ≥ 2.0 cm (shortest axis) to ≤ 6.0 cm (longest axis), as qualified by the central reading center.
• An ECOG Performance Status of 0 to 1 and Karnofsky Performance Status of 80 - 100.
• Study participants' ≥ 18 years of age at screening.
• To commence first-line standard gemcitabine and nab-paclitaxel chemotherapy, or gemcitabine alone, (per standard of care (SoC) according to the approved prescribing schedule), within 14 days post enrollment, with OncoSil™ implantation to occur during the fourth (4th) week of the first chemotherapy cycle.
• Provide signed Informed Consent.
• Willing and able to complete study procedures within the study timelines.
• Adequate renal function: serum creatinine less than 1.5 x upper limit of normal (ULN).
• Adequate liver function: serum liver transaminases ≤ 3 × ULN and serum bilirubin ≤ 1.5 × ULN*.
• For study participants with recent biliary obstruction treated by drainage (e.g. stent), serum bilirubin of > 1.5 x ULN will be accepted for study entry provided that serial levels demonstrate clear improvement. In addition, chemotherapy should not be commenced until serum bilirubin is ≤ 1.5 × ULN.
• Adequate bone marrow function: white blood cells (WBCs) ≥ 3,000/mm3, absolute neutrophil count (ANC) ≥ 1,500/mm3, hemoglobin ≥ 9 g/dL, and platelets ≥ 100,000/mm3.
• Life expectancy of at least 3 months at the time of screening as judged by the investigator.
• Treated with or eligible to commence prophylactic treatment with a proton-pump inhibitor prior to implantation, and to continue to receive treatment for at least 6 months post implantation.
• Not pregnant, and if of childbearing potential, agrees to use adequate birth control (hormonal or barrier method of birth control or abstinence) prior to study entry and during the study and agrees not to donate sperm or ova, for the duration of the study and 12 months post implantation of the investigational device.

You may not qualify if…

• Evidence of distant metastases, based on review of baseline CT scan, as determined by the central reading center.
• More than one primary lesion.
• Any prior radiotherapy or chemotherapy for pancreatic cancer.
• Use of other investigational agent at the time of screening, or within 30 days or five half-lives of Screening Visit 1, whichever is longer.
• Pregnant or lactating.
• In the opinion of the investigator, EUS directed implantation posing undue study participant risk. This includes:
• where previous EUS-FNA was considered technically too difficult to perform;
• imaging demonstrates multiple collateral vessels surrounding or adjacent to the target tumor within the pancreas;
• presence (or significant risk) of varices near to the target tumor. Note: The feasibility of implantation of the target tumor and assessment of risk can be conducted at any time between Screening Visit 1 and the implantation date. A study participant should be considered for withdrawal prior to and including at the time of OncoSil™ treatment, if any of the above risk features become apparent following study participant screening and/or enrolment.
• History of malignancy, treated or untreated, within the past five years whether or not there is evidence of local recurrence or metastases, with the exception of basal cell carcinoma of the skin and cervical carcinoma in situ.
• Evidence of radiographic invasion into stomach or duodenum (if not certain, confirmation must be obtained prior to enrolment).
• A known history of hypersensitivity to silicon or phosphorous, or any of the OncoSil™ components.
• Any other health condition that would preclude participation in the study in the judgement of the investigator.

Where it is running

• Cedars Sinai Department of Radiation Oncology — Los Angeles, California, United States
• Moffitt Cancer Centre — Tampa, Florida, United States
• Johns Hopkins Hospital — Baltimore, Maryland, United States
• MD Anderson Cancer Center — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.